Prognostic value of low muscle mass at the 12th thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study

Sung-Soo Park; Daehun Kwag; Jung Yeon Lee; Young-Woo Jeon; Seung-Ah Yahng; Seung-Hwan Shin; Seo Yeon Youn; Chang-Ki Min

doi:10.4274/dir.2023.232097

Prognostic value of low muscle mass at the 12^th thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study

Diagn Interv Radiol. 2023 Jul 20;29(4):596-608. doi: 10.4274/dir.2023.232097. Epub 2023 Jun 14.

Authors

Sung-Soo Park¹, Daehun Kwag¹, Jung Yeon Lee¹, Young-Woo Jeon², Seung-Ah Yahng³, Seung-Hwan Shin⁴, Seo Yeon Youn⁵, Chang-Ki Min¹

Affiliations

¹ Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
² Department of Hematology, Yeoido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
³ Department of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
⁴ Department of Hematology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
⁵ Department of Radiology, Seoul National University Hospital and Seoul National University College of Medicine; Seoul, Republic of Korea.

Abstract

Purpose: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscle index (PMI) at the 12^th thoracic vertebra (T12) level is a reliable prognostic marker in NDMM after chemotherapy.

Methods: A multi-center registry database was retrospectively analyzed. Between 2009 and 2020, 190 patients with chest computed tomography images underwent frontline ASCT following induction therapy. The PMI was defined as the value of the paraspinal muscle area at the T12 level divided by the square of the patient's height. The cut-off value indicating a low muscle mass was sex-specific, using the lowest quintiles.

Results: Of the 190 patients, 38 (20%) were in the low muscle mass group. The low muscle mass group had a lower 4-year overall survival (OS) rate than the non-low muscle mass group (68.5% vs. 81.2%; P = 0.074). The median progression-free survival (PFS) in the low muscle mass group was significantly shorter compared with the non-low muscle mass group (23.3 months vs. 29.2 months; P = 0.029). The cumulative incidence of transplant-related mortality (TRM) was significantly higher in the low muscle mass group than in the non-low muscle mass group (4-year probability of TRM incidence, 10.6% vs. 0.7%; P < 0.001). In contrast, no significant difference in the cumulative incidence of disease progression was found between the two groups. Multivariate analysis revealed that low muscle mass was associated with significant negative outcomes for OS [(hazard ratio (HR): 2.14; P = 0.047], PFS (HR: 1.78; P = 0.012), and TRM (HR: 12.05; P = 0.025).

Conclusion: Paraspinal muscle mass may have a prognostic role in NDMM patients who undergo ASCT. Patients with low paraspinal muscle mass have lower survival outcomes compared to non-low muscle mass group.

Keywords: Sarcopenia; autologous; computed tomography; myeloma; thoracic; transplantation.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Hematopoietic Stem Cell Transplantation* / methods
Humans
Male
Multiple Myeloma* / diagnostic imaging
Multiple Myeloma* / therapy
Muscles
Prognosis
Retrospective Studies
Transplantation, Autologous